VALEANT PHARMACEUTICALS INTL's ticker is VRX and the CUSIP is 91911K102. A total of 365 filers reported holding VALEANT PHARMACEUTICALS INTL in Q3 2016. The put-call ratio across all filers is 0.92 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2018 | $1,000 | – | 25 | 0.0% | 0.00% | – |
| Q1 2018 | $0 | -100.0% | 25 | 0.0% | 0.00% | – |
| Q4 2017 | $1,000 | – | 25 | 0.0% | 0.00% | – |
| Q3 2017 | $0 | – | 25 | 0.0% | 0.00% | – |
| Q2 2017 | $0 | – | 25 | 0.0% | 0.00% | – |
| Q1 2017 | $0 | – | 25 | 0.0% | 0.00% | – |
| Q4 2016 | $0 | -100.0% | 25 | 0.0% | 0.00% | -100.0% |
| Q3 2016 | $1,000 | -50.0% | 25 | -77.9% | 0.00% | 0.0% |
| Q2 2016 | $2,000 | -33.3% | 113 | +352.0% | 0.00% | -50.0% |
| Q4 2015 | $3,000 | -82.4% | 25 | -73.4% | 0.00% | -80.0% |
| Q3 2015 | $17,000 | -46.9% | 94 | -35.6% | 0.01% | -44.4% |
| Q2 2015 | $32,000 | +33.3% | 146 | -14.6% | 0.02% | +20.0% |
| Q4 2014 | $24,000 | +9.1% | 171 | 0.0% | 0.02% | +7.1% |
| Q3 2014 | $22,000 | +10.0% | 171 | +5.6% | 0.01% | +16.7% |
| Q2 2014 | $20,000 | -9.1% | 162 | -4.7% | 0.01% | -14.3% |
| Q1 2014 | $22,000 | – | 170 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Brave Warrior Advisors | 5,701,010 | $1,266,479,000 | 36.57% |
| Ruane, Cunniff & Goldfarb | 33,884,050 | $7,527,342,000 | 35.90% |
| LeVasseur Capital Partners LLC | 188,804 | $41,943,000 | 34.97% |
| Pershing Square Capital Management | 19,473,933 | $4,326,134,000 | 29.95% |
| FARLEY CAPITAL L.P. | 141,020 | $31,328,000 | 24.16% |
| Ratan Capital Management LP | 1,038,033 | $230,599,000 | 21.97% |
| Marble Arch Investments | 1,069,000 | $237,478,000 | 20.47% |
| Arrow Capital Management, LLC | 144,461 | $32,092,000 | 18.04% |
| Tesuji Partners | 1,368,040 | $303,910,000 | 17.93% |
| ValueAct Holdings | 14,994,261 | $3,330,975,000 | 17.54% |